Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 8, 2013

CollabRx, GeneInsight to Co-Market Informatics Solution

  • CollabRx and GeneInsight will together deliver an informatics solution to support interpretation and reporting of genetic variants from sequencing-based tests, the firms today announced.

    The companies said their joint initiative is meant to support sequencing, interpretation, and reporting in the clinical laboratory. Under the terms of the agreement, CollabRx medical and scientific content will be made accessible through the GeneInsight knowledge management platform. Together, the firms will make this offering available to the clinical lab market. Financial terms of the agreement were not disclosed.

    "We are excited to work with GeneInsight to provide a key medical informatics capability to the genetic testing laboratory market to accelerate adoption of next-generation sequencing-based tests for cancer and beyond," Thomas Mika, CollabRx CEO, said in a statement.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »